View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
CytoTherapeutics, Inc.
________________________________________
(Name of Issuer)
Common Stock
________________________________________
(Title of Class of Securities)
23292310
_________________________
(CUSIP Number)
Check the following box if a fee is being paid with this
statement []. (A fee is not required only if the filing person:
(1) has a previous statement on file reporting beneficial
ownership of more than five percent of the class securities
described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d - 7.)
* The remainder of the cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
Page 1 of 5 Pages
CUSIP No. 23292310 13G Page 2 of 5 Pages
__________ ___ ___
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
State Street Research & Management Company
#13-31424135
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Reporting Person is a corporation organized under Delaware
laws. Principal office of Reporting Person is in Boston, MA.
5. SOLE VOTING POWER
522,500
NUMBER OF
SHARES 6. SHARED VOTING POWER
BENEFICIALLY - 0 -
OWNED BY EACH
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 534,000
8. SHARED DISPOSITIVE POWER
- 0 -
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
534,000
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.86%
12. TYPE OF REPORTING PERSON*
Investment Adviser
*SEE INSTRUCTION BEFORE FILLING OUT
SCHEDULE G
Item 1 (a). Name of Issuer
CytoTherapeutics, Inc.
Item 1 (b). Address of Issuer's Principal Office
Two Richmond Square
Providence, RI 02906
Item 2 (a). Name of Person Filing
State Research & Management Company
Item 2 (b) Address of Principal Business Office, or if
none, Residence
One Financial Center, 30th Floor
Boston, MA 02111-2690
Item 2 (c). Citizenship
Reporting Person is a corporation organized under
Delaware laws. Principal office of Reporting Person is in
Boston, MA
Item 2 (d). Title of Class of Securities
Common Stock
Item 2 (e). CUSIP Number
23292310
Item 3. If this statement is filed pursuant to Rules 13d-
1(b), or 13d-2(b), check whether the person filing is a:
(a) [ ] Broker or Dealer registered under Section 15 of the
Act
(b) [ ] Bank as defined in section 3 (a) (6) of the Act
(c) [ ] Insurance Company as defined in section 3 (a) (19)
of the Act
(d) [ ] Investment Company registered under section 8 of
the Investment Company Act
(e) [x] Investment Adviser registered under section 203 of
the Investment Advisers Act of 1940
(f) [ ] Employee Benefit Plan, Pension Fund which is
subject to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund: see section 240.13d-1
(b) (1) (ii) (F)
(g) [ ] Parent Holding Company, in accordance with section
240.13d-1 (b) (ii) (G) (Note: See Item 7)
(h) [ ] Group, in accordance with section 240.13d-1 (b) (1)
(ii) (H)
SCHEDULE G
Item 4. Ownership
If the percent of the class owned, as of December 31 of the year
covered by the statement, or as of the last day of any month
described in Rule 13d-1(b) (2), if applicable, exceeds five
percent, provide the following information as of that date and
identify those shares which there is a right to acquire.
(a) Amount Beneficially Owned: 534,000
(b) Percent of Class: 4.86%
(c) Number of shares as to which such persons has:
(i) sole power to vote or to direct the
vote: 522,500
(ii) shared power to vote or to direct the
vote: -0-
(iii) sole power to dispose or to direct the
disposition of: 534,000
(iv) shared power to dispose or to direct
the disposition of: -0-
State Street Research & Management Company disclaims any
beneficial interest in any of the foregoing securities.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [x].
Item 6. Ownership of More than Five Percent on Behalf of
Another Person.
If any other person is known to have the right to receive or the
power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities, a statement to that effect
should be included in response to this item and, if such interest
relates to more than five percent of the class, such person
should be identified. A listing of the shareholders of an
investment company registered under the Investment Company Act of
1940 or the beneficiaries of employee benefit plan, pension fund
or endowment fund is not required.
All foregoing shares are in fact owned by clients of State Street
Research & Management Company
SCHEDULE G
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company.
If a parent holding company has filed this schedule, pursuant to
Rule 13d-1(b) (ii) (G), so indicate under Item 3 (g) and attach
an exhibit stating the identity and the Item 3 classification of
the relevant subsidiary. If a parent holding company has filed
this schedule pursuant to Rule 13d-1(c), attach an exhibit
stating the identification of the relevant subsidiary.
Inapplicable
Item 8. Identification and Classification of Members of the
Group.
If a group has filed this schedule pursuant to Rule 13d-1 (b)
(ii) (H), so indicate under Item 3(b) and attach an exhibit
stating the identity and Item 3 classification of each member of
the group. If a group has filed this schedule pursuant to Rule
13d-1(c), attach an exhibit stating the identity of each member
of the group.
Inapplicable
Item 9. Notice of Dissolution of Group.
Inapplicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired for the purpose
of and do not have the effect of changing or influencing the
control of the issuer of such securities and were not acquired in
connection with or as a participant in any transaction having
such purposes or effect.
Signature.
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: February 13, 1996
Signature: /s/ Richard D. Shoemaker
Richard D. Shoemaker
Sr. Vice President